Seeking Alpha

Inhibitex (INHX), which more than doubled on Friday thanks to positive trial data for its...

Inhibitex (INHX), which more than doubled on Friday thanks to positive trial data for its hepatitis C drug, gains another 12% premarket after Deutsche lifts its PT to $15 (75% above Friday's close), arguing the trial data will help drive market share gains, and additional positive data could act as new catalysts.
From other sites
Comments (1)
  • phoneranger
    , contributor
    Comments (350) | Send Message
     
    It figures that someone knew something. Maybe these guys. http://bit.ly/siymfu
    7 Nov 2011, 08:38 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector